

# Lefamulin Activity Against Gram-Positive Pathogens Collected in the 2017 Global SENTRY Antimicrobial Surveillance Program

Nabriva Therapeutics  
Dublin, Ireland  
www.nabriva.com


Susanne Paukner,<sup>1</sup> Steven P. Gelone,<sup>2</sup> S. J. Ryan Arends,<sup>3</sup> Helio S. Sader<sup>3</sup>

<sup>1</sup>Nabriva Therapeutics GmbH, Vienna, Austria; <sup>2</sup>Nabriva Therapeutics US, Inc., King of Prussia, PA, USA; <sup>3</sup>JMI Laboratories, North Liberty, IA, USA

## INTRODUCTION & PURPOSE

- Pneumonia is a major cause of morbidity and mortality in adults and children around the world.<sup>1-5</sup> Although antibiotic resistance rates vary by geographic region, rates are rising worldwide, creating a need for new therapies to treat community-acquired bacterial pneumonia (CABP)<sup>3-5</sup>
- Streptococcus pneumoniae* is the most commonly isolated bacterial pathogen from patients with CABP, with prevalences that vary by geographic region. Other causes of CABP include *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Staphylococcus aureus*, as well as atypical pathogens<sup>2,5</sup>
- Lefamulin (LEF), the first pleuromutilin antibiotic to be approved for intravenous (IV) and oral treatment of adults with CABP,<sup>6</sup> selectively inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit at the A- and P-sites in the peptidyl transferase center<sup>7,8</sup> (Figure 1)
- In patients with CABP, LEF demonstrated noninferiority to moxifloxacin in the IV-to-oral switch Lefamulin Evaluation Against Pneumonia (LEAP) 1 phase 3 study<sup>9</sup> and in the LEAP 2 oral-only phase 3 study<sup>10</sup>
- The objective of this study was to evaluate the in vitro activity of LEF and comparators against a contemporary global set of gram-positive pathogens

Figure 1. (A) Structure of Lefamulin and (B) Lefamulin in the Peptidyl Transferase Center of the Large Ribosomal Subunit



## RESULTS (continued)

Table 1. Activity of Lefamulin and Comparators Against *Streptococcus pneumoniae*

Antimicrobial Agent	MIC <sub>50/90</sub> (µg/mL)	% Susceptible per CLSI (M100, 2019)			
		USA	Europe	Latin America	Asia-Pacific
<i>S. pneumoniae</i>	n=2095	n=832	n=950	n=113	n=200
Lefamulin	0.12/0.25	[100.0]*	[100.0]*	[100.0]*	[100.0]*
Amoxicillin-clavulanic acid	≤0.03/2	94.8	93.2	88.5	90.9
Azithromycin	0.06/>4	55.4	76.2	67.0	38.2
Ceftaroline	≤0.008/0.12	100.0	99.9	99.1	100.0
Ceftriaxone	0.03/1	85.8 <sup>†</sup> 96.6 <sup>†</sup>	86.5 <sup>†</sup> 96.1 <sup>†</sup>	81.4 <sup>†</sup> 92.0 <sup>†</sup>	69.3 <sup>†</sup> 84.9 <sup>†</sup>
Clindamycin	≤0.25/>2	85.4	81.9	81.4	56.0
Erythromycin	0.03/>16	55.4	76.3	67.3	38.0
Levofloxacin	1/2	98.9	97.5	100.0	97.0
Moxifloxacin	0.12/0.25	99.2	98.1	100.0	98.0
Penicillin	0.03/2	63.9 <sup>§</sup> 63.9 <sup>¶</sup>	71.9 <sup>§</sup> 71.9 <sup>¶</sup>	62.8 <sup>§</sup> 62.8 <sup>¶</sup>	44.5 <sup>§</sup> 44.5 <sup>¶</sup>
Tetracycline	0.5/>4	79.9	77.4	70.8	40.0
Tigecycline	0.06/0.06	94.6 <sup>‡</sup>	94.0 <sup>‡</sup>	94.7 <sup>‡</sup>	89.5 <sup>‡</sup>
Trimethoprim-sulfamethoxazole	0.25/>4	73.6	73.8	60.2	59.0

% Susceptibility: ■ ≤30.0% ■ 30.1%–50.0% ■ 50.1%–60.0% ■ 60.1%–70.0% ■ 70.1%–85.0% ■ >85.0%  
 CLSI=Clinical and Laboratory Standards Institute; MIC<sub>50/90</sub>=minimum concentration at which 50% and 90% of isolates were inhibited.  
 \*Percentage inhibited at proposed lefamulin breakpoint of ≤1 µg/mL for *S. pneumoniae* is shown in brackets for comparison purposes only. †Using meningitis breakpoints. ‡Using oral breakpoints. ‡Using parenteral, meningitis breakpoints. ‡Using parenteral, nonmeningitis breakpoints. ‡US Food and Drug Administration breakpoints accessed February 2018.

Table 2. Activity of Lefamulin and Comparators Against β-Hemolytic *Streptococcus* spp.

Antimicrobial Agent	MIC <sub>50/90</sub> (µg/mL)	% Susceptible per CLSI (M100, 2019)			
		USA*	Europe*	Latin America†	Asia-Pacific†
β-hemolytic <i>Streptococcus</i> spp.	n=430	n=145	n=145	n=70	n=70
Lefamulin	0.03/0.03	[100.0]‡	[100.0]‡	[100.0]‡	[97.1]‡
Ceftriaxone	0.03/0.06	100.0	100.0	100.0	100.0
Clindamycin	≤0.25/>2	82.8	83.4	91.4	82.9
Daptomycin	≤0.06/0.25	100.0	100.0	100.0	100.0
Erythromycin	0.03/>16	65.5	77.9	78.6	80.0
Levofloxacin	1/1	100.0	99.3	88.6	97.1
Linezolid	1/2	100.0	100.0	100.0	100.0
Meropenem	0.015/0.06	100.0	100.0	100.0	100.0
Moxifloxacin	0.12/0.25	–	–	–	–
Penicillin	0.015/0.06	100.0	100.0	100.0	100.0
Tigecycline	0.06/0.06	100.0 <sup>§</sup>	100.0 <sup>§</sup>	100.0 <sup>§</sup>	100.0 <sup>§</sup>
Trimethoprim-sulfamethoxazole	≤0.12/0.25	–	–	–	–
Vancomycin	0.5/0.5	100.0	100.0	100.0	100.0

% Susceptibility: ■ ≤30.0% ■ 30.1%–50.0% ■ 50.1%–60.0% ■ 60.1%–70.0% ■ 70.1%–85.0% ■ >85.0%  
 CLSI=Clinical and Laboratory Standards Institute; MIC<sub>50/90</sub>=minimum concentration at which 50% and 90% of isolates were inhibited.  
 \*Organisms included: *Streptococcus agalactiae* (n=60), *S. dysgalactiae* (n=25), and *S. pyogenes* (n=60). †Organisms included: *S. agalactiae* (n=30), *S. dysgalactiae* (n=10), and *S. pyogenes* (n=30). ‡Percentage inhibited at proposed lefamulin breakpoint of ≤0.25 µg/mL for β-hemolytic *Streptococcus* spp. is shown in brackets for comparison purposes only. ‡US Food and Drug Administration breakpoints accessed February 2018.

Table 3. Activity of Lefamulin and Comparators Against *Staphylococcus aureus*

Antimicrobial Agent	MIC <sub>50/90</sub> (µg/mL)	% Susceptible per CLSI (M100, 2019)			
		USA	Europe	Latin America	Asia-Pacific
<i>S. aureus</i>	n=1544	n=537	n=506	n=251	n=250
Lefamulin	0.06/0.12	[99.4]*	[99.4]*	[99.2]*	[100.0]*
Azithromycin	0.5/>32	43.2	76.5	55.0	65.2
Ceftaroline	0.25/1	97.0 <sup>†</sup>	97.2 <sup>†</sup>	94.4 <sup>†</sup>	89.6 <sup>†</sup>
Clindamycin	0.06/>2	83.2	96.2	85.3	82.8
Doxycycline	0.12/0.5	98.1	99.0	99.6	88.8
Erythromycin	0.25/>8	42.6	76.1	55.0	64.8
Gentamicin	≤1/≤1	97.0	95.5	90.0	82.4
Levofloxacin	0.25/>4	62.9	83.8	82.1	75.6
Linezolid	1/2	100.0	100.0	100.0	100.0
Moxifloxacin	≤0.06/4	63.1	84.0	82.9	75.6
Oxacillin	0.5/>2	55.1	82.6	74.9	58.8
Tigecycline	0.06/0.12	100.0 <sup>‡</sup>	100.0 <sup>‡</sup>	100.0 <sup>‡</sup>	100.0 <sup>‡</sup>
Trimethoprim-sulfamethoxazole	≤0.5/≤0.5	97.8	99.4	99.6	95.6
Vancomycin	1/1	100.0	100.0	100.0	100.0
MRSA	n=495	n=241	n=88	n=63	n=103
Lefamulin	0.06/0.12	[98.8]*	[96.6]*	[98.4]*	[100.0]*
Azithromycin	>32/>32	13.3	43.2	27.0	39.8
Ceftaroline	0.5/2	93.4 <sup>†</sup>	84.1 <sup>†</sup>	77.4 <sup>†</sup>	74.8 <sup>†</sup>
Clindamycin	0.06/>2	70.1	79.5	52.4	61.2
Doxycycline	0.12/2	97.5	96.6	98.4	73.8
Erythromycin	>8/>8	12.9	43.2	27.0	38.8
Gentamicin	≤1/>8	95.4	85.2	76.2	67.0
Levofloxacin	>4/>4	30.7	30.7	38.1	45.6
Linezolid	1/2	100.0	100.0	100.0	100.0
Moxifloxacin	2/>4	31.1	30.7	39.7	45.6
Oxacillin	>2/>2	0.0	0.0	0.0	0.0
Tigecycline	0.06/0.25	100.0 <sup>‡</sup>	100.0 <sup>‡</sup>	100.0 <sup>‡</sup>	100.0 <sup>‡</sup>
Trimethoprim-sulfamethoxazole	≤0.5/≤0.5	95.4	98.9	98.4	91.3
Vancomycin	1/1	100.0	100.0	100.0	100.0

% Susceptibility: ■ ≤30.0% ■ 30.1%–50.0% ■ 50.1%–60.0% ■ 60.1%–70.0% ■ 70.1%–85.0% ■ >85.0%  
 CLSI=Clinical and Laboratory Standards Institute; MIC<sub>50/90</sub>=minimum concentration at which 50% and 90% of isolates were inhibited; MRSA=methicillin-resistant *S. aureus*.  
 \*Percentage inhibited at proposed lefamulin breakpoint of ≤0.5 µg/mL for *S. aureus* is shown in brackets for comparison purposes only. †Intermediate interpreted as susceptible-dose dependent. ‡US Food and Drug Administration breakpoints accessed February 2018.

Table 4. Activity of Lefamulin and Comparators Against Coagulase-Negative *Staphylococcus* spp.

Antimicrobial Agent	MIC <sub>50/90</sub> (µg/mL)	% Susceptible per CLSI (M100, 2019)			
		USA*	Europe†	Latin America‡	Asia-Pacific§
Coagulase-Negative <i>Staphylococcus</i> spp.	n=268	n=83	n=82	n=55	n=48
Lefamulin	0.06/0.5	[92.8]	[96.3]	[94.5]	[91.7]
Azithromycin	32/>32	34.1	45.1	23.6	45.8
Ceftaroline	0.25/1	–	–	–	–
Clindamycin	0.06/>2	66.3	81.7	61.8	72.9
Daptomycin	0.25/0.5	100.0	100.0	100.0	100.0
Doxycycline	0.25/4	88.0	92.7	96.4	91.7
Erythromycin	>8/>8	32.5	45.1	23.6	45.8
Gentamicin	≤1/>8	73.5	56.1	63.6	47.9
Levofloxacin	0.5/>4	63.9	39.0	54.5	60.4
Linezolid	1/1	97.6	98.8	100.0	100.0
Moxifloxacin	0.12/4	65.1	45.1	60.0	64.6
Oxacillin	>2/>2	39.8	30.5	21.8	20.8
Teicoplanin	2/8	97.6	98.8	100.0	91.7
Tigecycline	0.12/0.25	–	–	–	–
Trimethoprim-sulfamethoxazole	≤0.5/16	71.1	58.5	54.5	54.2
Vancomycin	2/2	100.0	100.0	100.0	100.0

% Susceptibility: ■ ≤30.0% ■ 30.1%–50.0% ■ 50.1%–60.0% ■ 60.1%–70.0% ■ 70.1%–85.0% ■ >85.0%  
 CLSI=Clinical and Laboratory Standards Institute; MIC<sub>50/90</sub>=minimum concentration at which 50% and 90% of isolates were inhibited.  
 \*Organisms included: *Staphylococcus capitis* (n=5), *S. cohnii* (n=2), *S. epidermidis* (n=45), *S. haemolyticus* (n=5), *S. hominis* (n=8), *S. lugdunensis* (n=9), *S. pettenkoferi* (n=1), *S. saprophyticus* (n=5), and *S. simulans* (n=3). †Organisms included: *S. capitis* (n=6), *S. cohnii* (n=1), *S. epidermidis* (n=42), *S. haemolyticus* (n=17), *S. hominis* (n=6), *S. lugdunensis* (n=9), and *S. pseudintermedius* (n=1). ‡Organisms included: *S. capitis* (n=4), *S. cohnii* (n=2), *S. epidermidis* (n=35), *S. haemolyticus* (n=6), *S. hominis* (n=5), *S. saprophyticus* (n=2), and *S. warneri* (n=1). §Organisms included: *S. capitis* (n=7), *S. epidermidis* (n=21), *S. haemolyticus* (n=8), *S. hominis* (n=7), *S. lugdunensis* (n=3), and *S. warneri* (n=2). ||Percentage inhibited at proposed lefamulin breakpoint of ≤0.5 µg/mL for coagulase-negative *Staphylococcus* spp. is shown in brackets for comparison purposes only.

## CONCLUSIONS

- LEF demonstrated potent activity against this contemporary (2017) worldwide collection of gram-positive pathogens
- LEF activity was unaffected by resistance to other antibiotic classes, including macrolides, fluoroquinolones, and β-lactam antibiotics, or by geographic region
- These in vitro data suggest that LEF may offer an important empiric monotherapy treatment option for CABP caused by these organisms, particularly in regions with high rates of resistance to antimicrobials commonly used for CABP

## REFERENCES

- World Health Organization. Pneumonia: Key Facts. Available at: <http://www.who.int/mediacentre/factsheets/fs331/en/>. Accessed July 19, 2019.
- Welte T, et al. *Thorax*. 2012;67(1):71-79.
- Song JH, et al. *Int J Antimicrob Agents*. 2011;38(2):108-117.
- File TM and Marrie TJ. *Postgrad Med*. 2010;122(2):130-141.
- Isturiz RE, et al. *Int J Infect Dis*. 2010;14(10):e852-856.
- Xenleta™ (lefamulin). Full Prescribing Information, Nabriva Therapeutics US, Inc., King of Prussia, PA, 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2019/211672s000\\_211673s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000_211673s000lbl.pdf). Accessed August 26, 2019.
- Eyal Z, et al. *Sci Rep*. 2016;6:39004.
- Schlünzen F, et al. *Mol Microbiol*. 2004;54(5):1287-1294.
- File TM Jr, et al. *Clin Infect Dis*. 2019; doi: 10.1093/cid/ciz090.[Epub ahead of print].
- Alexander E, et al. Oral lefamulin is safe and effective in the treatment of adults with community-acquired bacterial pneumonia (CABP): results of Lefamulin Evaluation Against Pneumonia (LEAP 2) study. Abstract LB6. Presented at: IDWeek, October 3–7, 2018; San Francisco, CA.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 28th informational supplement. Wayne, PA: 2018. M100Ed28E.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 29th edition. Wayne, PA: 2019. M100Ed29.

## Acknowledgments & Disclosures

Funding for development of this poster was provided by Nabriva Therapeutics to C4 MedSolutions, LLC (Yardley, PA), a CHC Group company. Susanne Paukner and Steven P. Gelone are employees/stockholders of Nabriva Therapeutics plc. S. J. Ryan Arends and Helio S. Sader are employees of JMI Laboratories, which was contracted by Nabriva Therapeutics to conduct these analyses.



Scan this QR code with your electronic device to receive a PDF file of the poster or visit [posters.chcinc.com/SENTRY2017\\_by\\_region](https://posters.chcinc.com/SENTRY2017_by_region)